

## Fiber-optic immunosensor for detection of Crimean-Congo Hemorrhagic fever IgG antibodies in patients

Firoz Algaar, Evgeni Eltzov, Marina M. Vdovenko, Ivan Yurievich Sakharov,  
Luka Fajs, Manfred Weidmann, Ali Mirazimi, and Robert S. Marks

*Anal. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.analchem.5b01728 • Publication Date (Web): 07 Jul 2015

Downloaded from <http://pubs.acs.org> on July 14, 2015

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1  
2  
3  
4  
5  
6  
7 **Fiber-optic immunosensor for detection of Crimean-Congo Hemorrhagic**  
8 **fever IgG antibodies in patients**  
9

10  
11 Firoz Algaar.<sup>a</sup>, Evgeni Eltzov<sup>b,c</sup>, Marina M. Vdovenko<sup>d</sup>, Ivan Yu. Sakharov<sup>d</sup>, Luka Fajs<sup>c</sup>,  
12 Manfred Weidmann<sup>e</sup>, Ali Mirazimi<sup>f,g,h,j</sup>, and Robert S. Marks<sup>a,b,c,k,m\*</sup>  
13  
14

15  
16 <sup>a</sup> Department of Environmental Engineering, Ben-Gurion University of the Negev, Beer-  
17 Sheva 84105, Israel  
18

19 <sup>b</sup> Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-  
20 Sheva 84105, Israel  
21

22 <sup>c</sup> School of Material Science and Engineering, Nanyang Technology University, Nanyang  
23 Avenue, 639798, Singapore  
24

25 <sup>d</sup> Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow,  
26 Russia  
27

28 <sup>e</sup> Institute of Aquaculture, University of Stirling, Stirling, United Kingdom  
29

30 <sup>f</sup> Public Health Agency of Sweden, Stockholm, Sweden  
31

32 <sup>g</sup> Karolinska Institute, Stockholm, Sweden  
33

34 <sup>h</sup> Institute for Clinical and Experimental Medicine, Linköping University, Linköping,  
35 Sweden  
36

37 <sup>j</sup> National Veterinary Institute, Uppsala, Sweden  
38

39 <sup>k</sup> National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev,  
40 Beer-Sheva, Israel  
41

42 <sup>m</sup> The Ilse Katz Center for Meso and Nanoscale Science and Technology, Ben-Gurion  
43 University of the Negev, Beer-Sheva, Israel  
44  
45  
46  
47  
48

49 \* Corresponding author  
50

51 e-mail: rsmarks@bgu.ac.il  
52

53 Tel: +972-8-6477182  
54  
55  
56  
57  
58  
59  
60

**Abstract**

Crimean-Congo hemorrhagic fever (CCHF) is a severe viral disease with high fatality rate. CCHF virus is endemic in parts of Africa, Asia, Middle East and southeastern Europe. Rapid diagnostics of CCHF is vital for appropriate clinical management and prevention of secondary spread from human-to-human. Currently, diagnostics relies on Real-Time RT-PCR and antibody or antigen detection using ELISA. These methods require trained personnel and expensive equipment and are not appropriate for point-of-care (POC) diagnostics. Furthermore there are no POC assays available for CCHF.

We developed a fiber-optic biosensor for the detection of CCHF IgG antibodies. In order to improve sensitivity, we optimized both the bioreceptor immobilization protocol and the chemiluminescence substrate formulation. The resulting protocol showed a 100-fold greater sensitivity for detection of CCHF antibodies. Finally, we evaluated the fiber-optic biosensor with two CCHF patient sera. We showed that the fiber-optic biosensor is 10-times more sensitive than colorimetric ELISA and is able to detect both patients with high and low levels of IgG antibodies. We believe that the fiber-optic biosensor is a suitable alternative to ELISA as it is much more sensitive and makes it possible to detect small amount of antibodies at an early stage of infection, and can be integrated as a point-of-care diagnostic system of CCHF.

**Introduction**

Crimean-Congo hemorrhagic fever (CCHF) is a severe viral disease with an average case fatality rate of 5-30%. CCHF virus is the most widespread tick-borne virus in the world, with cases reported from Africa, Middle East, Asia, Russia and southeastern Europe. The virus is transmitted to humans mainly by infected ticks from the genus *Hyalomma* or by contact with blood or tissues from infected humans and animals. CCHF virus is classified as a BSL-4 agent due to its high pathogenicity, possibility of spread from human to human and because there is no effective treatment or vaccine available [1]. Rapid diagnostics are essential for effective infection control and prevention of spread of the disease from human to human. Namely, healthcare professionals are at high risk of

1  
2  
3 infection due to their close contact with patients especially during invasive and aerosol-  
4 forming interventions and many nosocomial transmissions have been reported <sup>1</sup>.

5  
6  
7 Quick diagnostics provide the basis for the implementation of proper infection control  
8 measures and patient management <sup>2-4</sup>. Currently the diagnostics of acute CCHF relies  
9 mainly on the detection of viral RNA with Real-Time RT-PCR. This method enables quick,  
10 sensitive and specific detection, but is not suitable for point of care (POC) diagnostics, as  
11 it requires trained personnel and expensive equipment <sup>5,6</sup>. Besides, these criteria are  
12 mostly not met in rural areas where CCHF is endemic <sup>7</sup>. Diagnostics of acute CCHF is also  
13 performed with ELISA for detection of IgG and IgM antibodies as well as CCHF virus  
14 nucleoprotein (NP) and rarely by virus isolation. Current serological assays provide  
15 reliable results and offer adequate sensitivity in clinical settings, however they all  
16 require trained personnel, are time consuming and not appropriate for POC diagnostics  
17 <sup>7</sup>. An ideal POC test for detection of CCHF IgG would have to exhibit sensitivity and  
18 specificity similar to or greater than the current sensitivity and specificity of standard in-  
19 house and commercial ELISA tests that ranges between 66.9–90.2% and 95.8–100.0%  
20 respectively <sup>5</sup>. Besides it would ideally give quantitative results, be easy to use, robust  
21 and offer maximum operational safety to the user.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
There is a need for point-of-care diagnostic assays allowing for quick and reliable,  
bedside diagnostics of CCHF. Fiber-optic biosensors present a suitable alternative to  
existing diagnostic options for CCHF due to their small size, diagnostic accuracy and low  
cost. Other POC technologies, such as lateral flow have similar advantages however they  
do not give quantitative results and have limited multiplexing capabilities. Optic fiber  
biosensors are quantitative and can easily be multiplexed, a feature that would enable  
the design of a multiple-target POC assay. The core of optic-fiber biosensor  
development is the immobilization of capture affine biomolecules (eg. antigen,  
antibodies, nucleic acids) at the endface and the tip of an optical fiber. Target molecules  
then bind to the capture biomolecules and these can also bind to complementary  
labeled detection biomolecules. After exposure to a substrate, the marker enzyme  
oxidizes it and a chemiluminescent glow is produced as a side reaction that is collected

1  
2  
3 by the optical fiber and transduced to the detector <sup>8</sup>. Previously we developed fiber-  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

by the optical fiber and transduced to the detector <sup>8</sup>. Previously we developed fiber-optic biosensors for sensitive detection of antibodies against Ebola virus, Rift Valley Fever virus, Dengue virus, West-Nile and Hepatitis C <sup>9-13</sup>. The aim of this study is to develop a fiber-optic biosensor for accurate detection of antibodies against CCHF virus NP and to optimize the fiber-optic immobilization procedures so as to enhance overall signal.

## Materials and methods

### Materials

Methyl alcohol (136805) was purchased by Bio-Lab (Israel), acetic acid (45731, 99.8% (v/v)) was purchased from Fluka, sulfuric acid (76649390, 95% (v/v)), hydrochloric acid (7647010, 37% (v/v)) and hydrogen peroxide solution (7722841, 35%(v/v)) were purchased from Acros Organic (USA). 3-(Glycidoxypropyl)trimethoxysilane (GPTMS)(440167, 98%(v/v)), sodium m-periodate (S1878), phosphate buffer saline (PBS)(P4417), sodium cyanoborohydride (71435), glycine (G7403), skim milk powder (SM)(70166), Luminol (A8511), 4-morpholinopyridine (MORP) (480657) and polyoxyethylene-sorbitan monolaurate (Tween<sup>®</sup> 20) (P7949) were purchased from Sigma Aldrich (Israel).

### CCHFV-N protein expression and purification

For expression 1-50ng of plasmid CCFNhisPET19# (provided by Ali Mirazimi) containing the nucleocapsid gene of CCHFV strain Ibr10200 was transformed into BL21 and plated out for overnight culture on LB amp plates at 37°C. Clones were picked and subsequently cultured overnight in 5ml LB amp at 37°C, 50ml LB amp culture for 24h at 28°C after transfer of 1 ml, and 500ml LB amp culture after transfer of 10 ml at 28°C during the following day until an OD<sub>260nm</sub> between 0.4-0.6 was reached (NanoDrop). Expression was induced with 1 mM IPTG and the culture continued at 28°C overnight. A bacterial pellet was harvested by centrifugation at 4000g / 20min, washed with PBS,

1  
2  
3 resuspended in 5ml buffer A2, disrupted at level 3.5 (Sonifier II W-250/W-450, Branson,  
4 USA) for 30 sec for 7 times on ice and finally centrifuged at 12.000g, 4°C for 25 min. The  
5 supernatant was transferred to equilibrated Ni-agarose (1.4ml Ni-agarose (Qiagen,  
6 Germany) washed twice with 10ml water and twice with buffer A1) and incubated for 2h  
7 at 4°C on a shaker. After one additional centrifugation step the agarose was  
8 resuspended in 1ml buffer A1 and transferred into an empty column (Biorad, Germany).  
9 The column was then successively washed with 20ml buffer B, 10ml buffer E1, and the  
10 protein was eluted with 8 fractions of 500µl buffer E2. (Buffer A (50 mM Tris (pH 8,0),  
11 500 mM NaCl , 5 mM MgCl , 10 % Glycerin, 0,1 % NP-40, 2mM Imidazol), buffer A1  
12 (bufferA + 140mM β-mercaptoethanol), buffer A2 (BufferA + 0.1mM PMSF), buffer B  
13 (buffer A1 + 28mM Imidazol), elution buffer E (20 mM Tris (pH 8.0), 100 mM NaCl, 5 mM  
14 MgCl, 20 % Glycerin), buffer E1 (buffer E, 2mM Imidazol), buffer E2 (buffer E, 250mM  
15 Imidazol). The protein concentration was determined by the Bradford method (BCA-  
16 Assay, Pierce, UK) after confirming a pure band on an SDS page-gel.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 **CCHF sera and antibodies**

33  
34 Inactivated sera from two confirmed CCHF cases, CCHFV positive rabbit sera against N  
35 protein (Andersson et.al 2004 J. Med Virol), recombinant CCHFV N protein (Andersson  
36 et.al 2004 J. Med Virol), anti-CCHFV monoclonal antibody against N protein and anti-  
37 CCHF polyclonal rabbit antibodies were all received from the Public Health Agency of  
38 Sweden. Human IgG was detected with donkey HRP-coupled anti-human IgG antibodies.  
39 Rabbit antibodies were detected with HRP-coupled goat anti-rabbit IgG HRP (Jackson  
40 ImmunoResearch Laboratories, USA).  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Optical fiber immobilization**

50  
51 We used SFS400/440B black Tefzel®Superguide G UV-Vis (Fiberguide Industries, Stirling,  
52 NJ, USA) optic fibers. The length of any single fiber used in the experiments was  
53 approximately 25 cm. Tefzel® jacket and silicon buffer were removed with a fiber  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 stripping tool (Micro-Strip<sup>®</sup>, from Micro-Electronics Inc., MA, USA), leaving a 0.5 cm  
4  
5 nude optical fiber core tip.  
6

7  
8 Optic fibers were prepared according to the reference protocol described by Liebes et  
9 al.<sup>14</sup>. Briefly, the fibers were cleaned by sonication in 1:1 (v/v) methanol/ 97% HCl  
10 solution for 10 min at 90°C and treated with piranha solution (7:3 [v/v] H<sub>2</sub>SO<sub>4</sub>/H<sub>2</sub>O<sub>2</sub>) to  
11 produce surface hydroxyl groups, rinsed with nanopure water and dried with nitrogen  
12 gas. Fiber surfaces were then silanized with (3-glycidoxypropyl)trimethoxysilane for 60  
13 min at 90°C. Fibers were treated with 11.6 mM hydrochloric acid for 60 min (formation  
14 of vicinal diols) and 100 mM sodium m-periodate dissolved in 10% (v/v) acetic acid for  
15 60 min at room temperature (oxidation to aldehyde). Fibers were then rinsed with  
16 deionized water and incubated with 1ml of 0.43µg/ml HRP (for assay optimization) or  
17 CCHFV NP (for assay validation) overnight at 4°C. Un-reacted aldehyde groups were  
18 blocked using 1 M glycine for 30 min at RT and the unsaturated amines were stabilized  
19 by a Schiff base with 0.3 M sodium cyanoborohydride for 60 min at RT.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Fiber-optic chemiluminescent and Colorimetric immunoassay**

32  
33 Instrument set-up for chemiluminescence measurements was performed as previously  
34 described [22, 23]. A Hamamatsu HC135-01 Photo Multiplier Tube (PMT) Sensor Module  
35 was used for chemiluminescence measurements in a light-tight box. The far end of the  
36 fiber was held by a fiber holder (FPH-DJ, Newport) and placed into an adjustable single-  
37 fiber mount (77837, Oriel). Real-time data acquisition was performed using LabView  
38 (version 3.1, National Instruments Corporation). Chemiluminescence detection was  
39 performed with the Immuno-star HRP chemiluminescent kit (170-5040, Bio-Rad  
40 Laboratories, France). Chemiluminescence readings were integrated for 1 s, measuring a  
41 mean value of photon counts during 15 s. Results are presented as the mean and  
42 standard deviation of relative light units (RLU). Colorimetric detection was performed  
43 using 100µl 3,3,5,5-tetramethylbenzidine (TMB) (T0440, Sigma Aldrich, Israel) and 50µl  
44 of 2N H<sub>2</sub>SO<sub>4</sub> afterwards in each well. Optical density readings at 450 were determined  
45 with a Labsystems Multiscan RC ELISA reader.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Protocol optimization

The initial immobilization protocol (Protocol 1)<sup>14</sup> was optimized in order to achieve maximum output chemiluminescence signal levels. For protocol optimization we immobilized 200 U/ml HRP on the fiber optic. Optimization steps are shown in Table 1. Steps with the highest chemiluminescence output comprise the optimized protocol (Protocol 2), which we used for the optic-fibre immobilization with CCHF virus NP.

We also evaluated the effect of two different HRP substrate compositions. We compared the output levels of the Immuno-star-HRPTM substrate (Bio-Rad), that includes 1:1 luminol/enhancer and stable peroxide buffer, and a substrate described by Vdovdenko et al.<sup>15</sup> that is based on the addition of two enhancers: SPTZ (sodium salt of 3-(10'-phenothiazinyl)propane-1-sulfonate) and MORP (4-morpholinopyridine). A total of 240µl substrate was added to each well.

### Fiber-optic immunoassay for detection of CCHF antibodies

Assay's sensitivity was evaluated with a 10<sup>2</sup> to 10<sup>6</sup> dilution range of Polyclonal Rabbit anti-CCHF virus antibodies. Briefly, 200 µl diluted antibodies were added per well (five sets of triplicates) and incubated for 60 min.

Sensitivity of the assay was further evaluated with two confirmed samples from two CCHF patients from Turkey. The samples were collected for routine diagnostic purposes in Turkey and development of diagnostic tools and their collection was approved by the governing ethical committee (Turkish Public Health Institution). Serum samples were chosen based on their initial serology results: high-level IgG for patient 1 (CDC ELISA, OD: 2) and low-level IgG for patient 2 (OD: 0,4).

Optic fibers were incubated with 200µl diluted serum (dilutions from 10<sup>3</sup> to 10<sup>6</sup>) for 60 min (three sets of triplicates). Unmodified fibers were used to check the level of background signal. Optic fiber tips were washed four times with PBST-BSA for a one-time 10 min, followed by a three time 3 min protocol. Fibers were then dipped into

1  
2  
3 200µl donkey anti-human IgG peroxidase-labeled antibodies (1/500) for 60 mi and  
4  
5 washed with PBS-Tween before chemiluminiscence detection as described above.  
6  
7

### 8 9 **CCHF IgG ELISA**

10  
11 Fiber-optic immunoassay for detection of CCHF virus antibodies performance was  
12 compared to the performance of CCHF IgG ELISA. MaxiSorp 96-well microtiter plates  
13 (Nunc) were coated with 100µl/well of CCHF virus NP. Plates were placed overnight at  
14 4°C. Plates were then washed three times with 100µl of PBS each. Each well was  
15 blocked by 150µl/well of blocking solution (1M glycine (w/v) in PBS buffer, pH 7.2) for  
16 1 h at 37°C. Plates were washed three times with 100µl 0.1%PBST containing 5% (w/v)  
17 skimmed milk (washing step). Serial dilutions ( $10^{-2}$ - $10^{-6}$ ) of anti-CCHF antibodies  
18 (100µL/well) were added in triplicates and incubated for 1 h at 37°C followed by a  
19 washing step. Goat anti-mouse IgG peroxidase-labeled antibodies (100 µl/well) ( $10^3$ )  
20 were added and incubated for 1 h at 37°C, followed by a washing step. Two different  
21 substrates were used. For colorimetric ELISA, we added 3,3',5,5' tetramethylbenzidine  
22 (TMB) (100 µl/well) and incubated at room temperature for 30 min in the dark. The  
23 reaction was stopped with 2N H<sub>2</sub>SO<sub>4</sub> (50 µl/well). Optical density reads at 450 nm  
24 (OD<sub>450</sub>) were determined with the Labsystems Multiscan RC ELISA reader. Results are  
25 presented as the mean and standard deviation of OD<sub>450</sub>.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results and Discussion

The aim of this study was to develop and optimize a fiber optic biosensor for detection of CCHF virus antibodies. As a starting point we used a previously described immobilization protocol (Protocol 1)<sup>14</sup> and optimized each step in order to maximize the chemiluminescence output. In the cleaning step we tested the effects of sonication and duration of methanol washing. We showed that sonication significantly increased the biosensor end point signal output (RLU 6857 vs. 1114 without sonication) and that methanol washing for 20 min was the most effective. Next we wanted to assess the efficacy of optical fiber activation (production of surface hydroxyl groups) using different activating solutions. Namely, we wanted to replace the piranha solution with a safer alternative as it is highly toxic and dangerous, requires special handling and disposal measures. However, our results show that the piranha solution was by far the most effective activator, with the biosensor output of 16669 RLU. Neither HCL, H<sub>2</sub>SO<sub>4</sub>, CH<sub>3</sub>COOH or H<sub>3</sub>PO<sub>4</sub> had comparable results (RLU: 3598, 9625, 1991, 5681, respectively). Piranha solution was therefore used in the optimized protocol (Protocol 2). Next step was the optimization of the silanization process. We tested 3 different temperatures (30°C, 60°C and 90°C) and 3 different durations (30 min, 60 min, 90 min) of silanization. We obtained the highest biosensor output at 60°C for 60 min (8660 RLU). In the last step we optimized the temperature and duration of treatment with sodium m-peroxidate. The highest biosensor output was achieved at 25°C for 90 min (20594 RLU). The results of the protocol optimization are shown in Table 1.

Next, we compared protocols 1 and 2 for their overall performance in the immunoassay, and as seen in Figure 1, the sensitivity of protocol 2 is 100-fold higher (limit of detection for protocol 1 is antibody dilution 10<sup>-4</sup> and for protocol 2 is 10<sup>-6</sup>). The results show that optimization steps had great influence on the overall efficacy of the immunoassay. Protocol 2 was therefore used for validation of the fiber-optic biosensor using patient sera.

1  
2  
3 We also compared two different substrate formulations with respect to the overall  
4 biosensor output. We wanted to assess if enhancers (SPTZ or MORP) added to the  
5 luminol/peroxide substrate, would enhance the biosensor's output, and indeed, as seen  
6 in figure 2, the addition of the two enhancers did increase the biosensor's output by  
7 roughly 10-fold. An additional advantage in using SPTZ/MORP enhancers is that they  
8 provide a more durable light signal that increases the biosensor's sensitivity<sup>16</sup>.  
9  
10

11  
12  
13 In the last step we evaluated the sensitivity of the developed fiber-optic biosensor for  
14 the detection of CCHF IgG antibodies in human sera. We tested the assay with both  
15 patients' sera. Fiber-optic biosensor detection was more sensitive than ELISAs. The  
16 lowest limit of detection of Patient 1 serum was 10-fold greater compared to ELISA,  
17 down to titer 1:1,000,000. The assay was also able to detect the low positive serum  
18 sample of Patient 2 down to titer 1:5,000 (Table 2).  
19  
20  
21  
22  
23  
24  
25  
26

27  
28 Our results show that our fiber-optic biosensor is a suitable alternative for ELISA, for the  
29 detection of CCHF virus IgG antibodies. The assay enables rapid and sensitive detection  
30 of CCHF antibodies and can be manufactured as a semi-disposable, point-of-care device.  
31 The technology also enables us to modify the device to enable detection of other  
32 biomolecules (e.g. CCHF RNA). Another advantage of the proposed biosensor is that it  
33 does not require trained personnel or expensive equipment for its operation. Today's  
34 diagnostic assays lack these features and are therefore available only at select  
35 diagnostic centers. However, the endemic areas of CCHF are mainly rural areas with  
36 limited access to these high-end diagnostic services. High pathogenicity of CCHF and the  
37 risk of human-to-human transmissions, especially in hospital settings, warrant the  
38 development of point-of-care devices that would enable quick, safe and reliable  
39 diagnostics of CCHF. The main advantage of the fiber optic biosensor is that it provides  
40 sensitive results and can be designed as a point-of-care device at a cost comparable to  
41 current standard ELISA assays. The assay could serve as a rapid, primary diagnostic tool  
42 for bedside CCHF diagnostics in endemic areas where extensive diagnostic equipment  
43 and trained personnel are not available. The fiber-optic biosensor could provide the  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

necessary solution, however further studies are needed to determine the actual clinical sensitivity and specificity of the assay on a larger scale.

### Acknowledgements

This project was funded by the CCH Fever Network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Program of the 7th Framework Program (Grant agreement no. 260427). We thank Doris Heidenreich for technical assistance and Gulay Korukluoğlu for the human serum samples.

### References

- (1) Tarantola, A.; Ergonul, O.; Tattevin, P.; Ergonul, O.; Whitehouse, C. A. Springer: Netherlands, 2006; pp. 281–294.
- (2) Pshenichnaya, N. Y.; Nenadskaya, S. A. *Int. J. Infect. Dis.* **2015**, *33C*, 120–122.
- (3) Papa, A.; Mirazimi, A.; Köksal, I.; Estrada-Pena, A.; Feldmann, H. J. *Clin. Virol.* **2014**.
- (4) Conger, N. G.; Paolino, K. M.; Osborn, E. C.; Rusnak, J. M.; Günther, S.; Pool, J.; Rollin, P. E.; Allan, P. F.; Schmidt-Chanasit, J.; Rieger, T.; Kortepeter, M. G. *Emerging Infect. Dis.* **2015**, *21*, 23–31.
- (5) Vanhomwegen, J.; Alves, M. J.; Zupanc, T. A.; Bino, S.; Chinikar, S.; Karlberg, H.; Korukluoğlu, G.; Korva, M.; Mardani, M.; Mirazimi, A.; Mousavi, M.; Papa, A.; Saksida, A.; Sharifi-Mood, B.; Sidira, P.; Tsergouli, K.; Wölfel, R.; Zeller, H.; Dubois, P. *Emerging Infect. Dis.* **2012**, *18*, 1958–65.
- (6) Escadafal, C.; Olschlager, S.; Avsic-Zupanc, T.; Papa, A.; Vanhomwegen, J.; Wolfel, R.; Mirazimi, A.; Teichmann, A.; Donoso-Mantke, O.; Niedrig, M. *PLoS neglected tropical diseases* *6*, e1706.
- (7) Bente, D. A.; Forrester, N. L.; Watts, D. M.; McAuley, A. J.; Whitehouse, C. A.; Bray, M. *Antiviral Res.* **2013**, *100*, 159–89.
- (8) Collings, A.; Caruso, F. *Reports on Progress in Physics* *60*, 1397–1445.
- (9) Sobarzo, A.; Paweska, J.; Herrmann, S.; Amir, T.; Marks, R.; Lobel, L. *Journal of Virological Methods* *146*, 327–334.
- (10) Konry, T.; Novoa, A.; Shemer-Avni, Y.; Hanuka, N.; Cosnier, S.; Lepellec, A.; Marks, R. S. *Anal. Chem.* **2005**, *77*, 1771–9.
- (11) Atias, D.; Liebes, Y.; Chalifa-Caspi, V.; Bremand, L.; Lobel, L.; Marks, R.; Dussart, P. *Sensors and Actuators, B: Chemical* **1899**, *140*, 206–215.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (12) Herrmann, S.; Leshem, B.; Landes, S.; Rager-Zisman, B.; Marks, R. S. *Talanta* **2005**, *66*, 6–14.
- (13) Petrosova, A.; Konry, T.; Cosnier, S.; Trakht, I.; Lutwama, J.; Rwaguma, E.; Chepurnov, A.; Mühlberger, E.; Lobel, L.; Marks, R. *Sensors and Actuators B: Chemical* **2007**, *122*, 578586.
- (14) Liebes, Y.; Amir, L.; Marks, R.; Banai, M. *Talanta* **1901**, *80*, 338–345.
- (15) Vdovenko, M.; Ciana, L.; Sakharov, I. *Analytical Biochemistry* *392*, 54–58.
- (16) Vdovenko, M.; Ciana, L.; Sakharov, I. *Biotechnology Journal* *5*, 886–890.

Table 1: Optimization steps for optical fiber immobilization (in bold are the parameters that define the optimized protocol 2)

Step	Optimization		Biosensor output [RLU]
Cleaning	Sonication	<b>With</b>	<b>6857 (39.72)</b>
		Without	1114 (15.92)
	Methanol	10 min	4710.17 (24.78)
		<b>20 min</b>	<b>13402.88 (16.86)</b>
		30 min	13141.38 (18.03)
Activation		HCL	3598 (7.6)
		<b>Piranha</b>	<b>16669 (31.8)</b>
		H <sub>2</sub> SO <sub>4</sub>	9625 (26.2)
		CH <sub>3</sub> COOH	1991 (26.4)
		H <sub>3</sub> PO <sub>4</sub>	5681 (16.34)
Silanization	30 min	30°C	1428 (32)
		60°C	2760 (50)
		90°C	1644 (33)
	<b>60 min</b>	30°C	1864 (37)
		<b>60°C</b>	<b>8660 (17)</b>
		90°C	2941 (46)
		90 min	30°C
		60°C	4198 (40)
		90°C	1204 (3)
	Sodium m-periodate	30 min	25°C
30°C			1870 (35.9)
60°C			1415 (16.4)
60 min		25°C	9086 (31.5)
		30°C	3357 (15.4)
		60°C	3465 (36.4)
<b>90 min</b>		<b>25°C</b>	<b>20594 (18.9)</b>
		30°C	7884 (33.4)
		60°C	3626 (26.1)

Table 2: Immunoassay results

Sample	Dilution	Fiber optic biosensor	ELISA
Patient 1	1:5000	+	+
	1:10000	+	+
	1:20000	+	+
	1:50000	+	+
	1:100000	+	+
	1:250000	+	-
	1:500000	+	-
	1:750000	+	-
1:1000000	+	-	
Patient 2	1:1000	+	ND
	1:5000	+	ND
	1:10000	-	ND
No serum control		-	-
Human serum control		-	-
Rabbit serum control		-	-
Positive control		+	+
No primary antibody		-	-
No secondary antibody		-	-

ND not determined




Figure 1: Immunoassay results for the comparison of immobilization protocols 1 and 2.




Figure 2: Immunoassay results for the comparison of two substrate formulations. Substrate A is a commercial luminol/peroxide formulation, substrate B includes two additional enhancers, SPTZ and MORP. NC= negative control.

For TOC only

Crimean-Congo hemorrhagic fever IgG		
dilution	Fiber optic biosensor	IgG ELISA
1:500	+	+
1:10000	+	+
1:20000	+	+
1:50000	+	+
1:100000	+	+
1:250000	+	-
1:500000	+	-
1:750000	+	-
1:1000000	+	-